Pomerantz Law Firm Warns Reckitt Benckiser Investors of Class Action Lawsuit and Key Deadlines

Pomerantz Law Firm's Notification to Reckitt Benckiser Investors

In a significant development for investors of Reckitt Benckiser Group Plc (OTCMKTS: RBGLY), the Pomerantz Law Firm has announced the initiation of a class action lawsuit against the company. This legal action raises serious concerns regarding allegations of securities fraud and potentially unlawful business practices. Investors who have incurred losses from their Reckitt investments are urged to take note of the upcoming critical deadlines and may have the opportunity to join the class action.

The esteemed firm has been recognized for its robust track record in securities litigation and is once again stepping up to advocate for investors' rights. Those affected are encouraged to contact Danielle Peyton at [email protected] or call 646-581-9980 for further information. Interested individuals should provide their mailing address, phone number, and details about their shares to facilitate the process.

Class Action Details

According to the lawsuit, there are claims that Reckitt and certain individuals in positions of authority within the company have engaged in securities fraud. The class period for those eligible to participate in the lawsuit spans the timeframe during which they purchased Reckitt’s securities. Investors have until August 4, 2025, to formally request their appointment as Lead Plaintiff. The complete details can be found in the filed complaint available at www.pomerantzlaw.com.

Background of the Case

Adding weight to the allegations are earlier legal troubles for Reckitt’s Mead Johnson subsidiary. On March 15, 2024, a jury in Illinois rendered a verdict imposing a $60 million penalty against Mead Johnson. The jury determined that the company displayed negligence by failing to inform consumers that its cow's milk-based formula significantly raised the risk of necrotizing enterocolitis (NEC) in premature infants. This ruling had immediate consequences for Reckitt, resulting in a sharp decline in the price of its American Depositary Shares (ADS), which fell nearly 14% on the same day.

Further compounding Reckitt's troubles, a similar lawsuit against Abbott Laboratories on July 29, 2024, resulted in a staggering $495 million verdict, asserting that Abbott's specialized baby formula also posed a risk of NEC. Following this announcement, Reckitt's ADS plummeted by approximately 9%, highlighting the unsettling climate that surrounds the company's operations and public perception.

With over 85 years of experience in corporate, securities, and antitrust class litigation, Pomerantz continues to exemplify its commitment to fighting against corporate misconduct. Founded by the influential Abraham L. Pomerantz, the firm has a long history of successfully securing multimillion-dollar settlements on behalf of class members affected by securities fraud.

Conclusion

Investors in Reckitt Benckiser Group Plc should be aware of their rights and the available resources as they navigate these turbulent legal waters. Pomerantz LLP is dedicated to ensuring that victims of corporate malpractice are represented and compensated fairly. As the class action progresses, stakeholders are encouraged to stay informed on developments, as changes could significantly impact their investments.

For more information about the class action and to keep in touch with developments in this case, visit www.pomlaw.com for the latest updates and guidance on potential legal recourse.